EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period

Mike Y Chen iD, Jeanette Du, Brian K Do, Mohsin H Ali iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0323253 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Mike Y Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University School of Medicine, Washington, DC, United States of America. Hauptthemen laut MEDLINE: COVID-19, Angiogenesis Inhibitors, Macular Degeneration. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Main objective Compare treatment outcomes of newly diagnosed neovascular age-related macular degeneration (nAMD) during and after the COVID-19 restrictions.

Methods

This retrospective study at the Retina Group of Washington analyzed nAMD patients treated with anti-VEGF therapy with ≥ 12 months of follow-up. Two groups were identified: 258 subjects diagnosed between March 2020-March 2022 (Group 1) and 376 subjects diagnosed after (Group 2). Primary outcomes were 12-month and final best-corrected visual acuity (BCVA), and number of injections in the first 12 months.

Results

Initial mean BCVA was 20/71 and 20/68 in Group 1 and Group 2, with median BCVA of 20/60 and 20/50, respectively. At 12 months, mean BCVA improved to 20/65 and 20/54 in Group 1 and Group 2, respectively (p = 0.086). Final mean BCVA was 20/76 for Group 1 and 20/58 for Group 2 (p = 0.010). The mean change in LogMAR BCVA from the time of conversion to last follow-up was + 0.03 for Group 1 and -0.08 for Group 2 (p = 0.007). Group 1 had fewer injections in the first year of therapy (8.67 vs. 9.21, p = 0.004). 38.8% of Group 1 reached BCVA ≥20/40 at 12 months, versus 48.9% for Group 2 (p = 0.011).

Conclusion

Patients diagnosed during the COVID-19 restrictions period had worse visual outcomes than those diagnosed thereafter. Multiple factors, including, but not limited to reduced treatment frequency, likely contributed to worse visual outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Angiogenesis InhibitorsMacular DegenerationHumansMaleFemaleAgedRetrospective StudiesVisual AcuityTreatment OutcomeAged, 80 and overSARS-CoV-2Middle AgedIntravitreal InjectionsBevacizumabVascular Endothelial Growth Factor A

Substanzen

Angiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Georgetown University School of Medicine, Washington, DC, United States of America.
  • Retina Group of Washington, Chevy Chase, Maryland, United States of America.

ORCID-Profile: Mike Y Chen, Mohsin H Ali

Zitieren

APA

Chen, M. Y., Du, J., Do, B. K., & Ali, M. H. (2025). Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period. PLOS One. https://doi.org/10.1371/journal.pone.0323253

Vancouver

Chen MY, Du J, Do BK, Ali MH. Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period. PLOS One. 2025. doi:10.1371/journal.pone.0323253

BibTeX
@article{Chen2025,
  author = {Chen, Mike Y and Du, Jeanette and Do, Brian K and Ali, Mohsin H},
  title = {Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0323253}
}
Kostenlos starten →